Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio Inc., a biopharma company based in South San Francisco, focused on the discovery and development of disease-modifying neuroprotective drugs, today announced the publication of research elucidating the molecular details of a conserved, NAD-dependent inhibitory mechanism that results in highly potent small molecule inhibitors of NAD hydrolases like SARM1 and CD38. . The publication also discloses several highly potent small molecule inhibitors of SARM1.” The study, titled “Uncompetitive, adduct forming SARM1 inhibitors are neuroprotective in preclinical models of nerve injury and disease”, by Bratkowski et al., was published online in Neuron and will appear in the November issue of the journal.